AU2012297589C1 - Liposomal compositions - Google Patents

Liposomal compositions Download PDF

Info

Publication number
AU2012297589C1
AU2012297589C1 AU2012297589A AU2012297589A AU2012297589C1 AU 2012297589 C1 AU2012297589 C1 AU 2012297589C1 AU 2012297589 A AU2012297589 A AU 2012297589A AU 2012297589 A AU2012297589 A AU 2012297589A AU 2012297589 C1 AU2012297589 C1 AU 2012297589C1
Authority
AU
Australia
Prior art keywords
composition
liposomes
chlorite
glycero
chlorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012297589A
Other languages
English (en)
Other versions
AU2012297589B2 (en
AU2012297589A1 (en
Inventor
Jurgen Arnhold
Tejas Desai
Dominic King-Smith
Rainer Martin
Robert Seifert
Andreas Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUVO RESEARCH GmbH
Original Assignee
Nuvo Res GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Res GmbH filed Critical Nuvo Res GmbH
Publication of AU2012297589A1 publication Critical patent/AU2012297589A1/en
Publication of AU2012297589B2 publication Critical patent/AU2012297589B2/en
Application granted granted Critical
Publication of AU2012297589C1 publication Critical patent/AU2012297589C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
AU2012297589A 2011-12-22 2012-12-21 Liposomal compositions Ceased AU2012297589C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579326P 2011-12-22 2011-12-22
US61/579,326 2011-12-22
PCT/IB2012/057645 WO2013093891A1 (en) 2011-12-22 2012-12-21 Liposomal chlorite or chlorate compositions

Publications (3)

Publication Number Publication Date
AU2012297589A1 AU2012297589A1 (en) 2013-07-11
AU2012297589B2 AU2012297589B2 (en) 2014-10-30
AU2012297589C1 true AU2012297589C1 (en) 2015-04-16

Family

ID=47630448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012297589A Ceased AU2012297589C1 (en) 2011-12-22 2012-12-21 Liposomal compositions

Country Status (11)

Country Link
US (1) US20130177629A1 (enExample)
EP (1) EP2793860A1 (enExample)
JP (1) JP2015502400A (enExample)
CN (1) CN104125826A (enExample)
AU (1) AU2012297589C1 (enExample)
BR (1) BR112014015333A8 (enExample)
CA (1) CA2857604A1 (enExample)
IN (1) IN2014DN05866A (enExample)
MX (1) MX2014007664A (enExample)
RU (1) RU2014130080A (enExample)
WO (1) WO2013093891A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2014037927A1 (en) * 2012-09-10 2014-03-13 Nuvo Research Gmbh Chlorate compositions and use of chlorate for treating radiation exposure
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
US11813234B2 (en) * 2015-08-20 2023-11-14 Oxo Translational Science Gmbh Use of chlorite to treat red blood cell diseases and indications mediated thereby
TWI719105B (zh) * 2016-01-04 2021-02-21 中央硏究院 基於酯化/皂化用於微脂體負載之方法
US20190142864A1 (en) * 2017-10-11 2019-05-16 California Institute Of Technology Methods and systems, for interfering with viability of bacteria and related antimicrobials and compositions
WO2019160519A2 (en) * 2018-02-15 2019-08-22 Yeditepe Universitesi Exosome isolation method by two phase fluid system
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
CN112716973A (zh) * 2019-10-28 2021-04-30 卢序 一种降低细胞还原应激的氧化剂的用途
TR202012260A2 (tr) * 2020-08-05 2020-10-21 Emin Zuemruetdal Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu
JP2025518546A (ja) * 2022-05-19 2025-06-17 ニューヴィヴォ， インコーポレイテッド 神経変性疾患のバイオマーカー

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000019981A1 (en) * 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
KR20030072766A (ko) * 2002-03-06 2003-09-19 (주)인터커머스 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법
US20070104798A1 (en) * 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3213389A1 (de) 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4551288A (en) 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4574084A (en) 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3625867C2 (de) 1986-07-31 1995-10-19 Elstner Erich F Prof Dr Verwendung von Tetrachlordecaoxid in der Ophthalmologie
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
EP0414663A4 (en) 1987-04-16 1991-07-17 The Liposome Company, Inc. Liposome continuous size reduction method and apparatus
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4851222A (en) 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5190822A (en) 1990-04-20 1993-03-02 Fuji Photo Film Co., Ltd. Surface-modifiable liposome and process for producing surface-modified liposome
US5206027A (en) 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
WO1992007959A1 (en) 1990-11-05 1992-05-14 Biowhittaker Inc. Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
JPH06206825A (ja) 1992-12-11 1994-07-26 Nippon Rooshiyon Kk 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤
ATE166573T1 (de) 1993-03-24 1998-06-15 Ciba Geigy Ag Verfahren zur herstellung einer liposomendispersion im hochdruckbereich
US6087171A (en) 1993-12-17 2000-07-11 Spinal Cord Society Method for inducing DNA synthesis in neurons
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6110666A (en) 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
ES2339421T3 (es) 1997-11-19 2010-05-20 Georgetown University Administracion genica mediante liposoma dirigido.
US6573101B1 (en) 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US6077502A (en) 1998-02-27 2000-06-20 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6251372B1 (en) 1998-02-27 2001-06-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6132702A (en) 1998-02-27 2000-10-17 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
MXPA01003507A (es) * 1998-10-08 2002-06-26 Hampar L Karagoezian Antimicrobiano sinergico, preparaciones dermatologicas y oftalmicas que contienen clorito y peroxido de hidrogeno.
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
IL148189A0 (en) 1999-08-18 2002-09-12 Oxo Chemie Ag Chemically-stabilized chlorite solutions for treating cancer and other diseases
JP2003508920A (ja) 1999-08-27 2003-03-04 マクロニックス・アメリカ・インコーポレーテッド ２ビット保存用の不揮発性記憶装置構造体及びその製造方法
AU1776801A (en) 1999-11-24 2001-06-04 Liposome Company, Inc., The Modular targeted liposomal delivery system
CA2733819A1 (en) 1999-12-30 2001-07-12 Judith K. Gwathmey Iron chelator delivery system
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
WO2003044214A2 (en) 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
ATE546148T1 (de) 2005-07-21 2012-03-15 Nuvo Res Ag Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
US8067035B2 (en) * 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
EP1971426A1 (de) 2006-01-11 2008-09-24 P & W Invest Vermögensverwaltungsgesellschaft mbH Hüllenmembran zur abgabe eines eingeschlossenen wirkstoffs, ein verfahren zur herstellung sowie deren verwendung
WO2008145376A1 (en) 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
US20110052655A1 (en) 2007-08-08 2011-03-03 Wilson Kurt Whitekettle Methods and vesicles for controlling protozoa
ES2613498T3 (es) * 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US20110177147A1 (en) 2010-01-21 2011-07-21 General Electric Company Stable biocidal delivery systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000019981A1 (en) * 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
US20070104798A1 (en) * 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
KR20030072766A (ko) * 2002-03-06 2003-09-19 (주)인터커머스 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법

Also Published As

Publication number Publication date
WO2013093891A1 (en) 2013-06-27
CA2857604A1 (en) 2013-06-27
BR112014015333A2 (pt) 2017-06-13
JP2015502400A (ja) 2015-01-22
CN104125826A (zh) 2014-10-29
AU2012297589B2 (en) 2014-10-30
RU2014130080A (ru) 2016-02-10
IN2014DN05866A (enExample) 2015-05-22
EP2793860A1 (en) 2014-10-29
MX2014007664A (es) 2015-05-11
BR112014015333A8 (pt) 2017-06-13
AU2012297589A1 (en) 2013-07-11
US20130177629A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
AU2012297589B2 (en) Liposomal compositions
CN112236134B (zh) 类胡萝卜素组合物及其用途
JP4555569B2 (ja) 増強された血中安定性を有する脂質キャリア組成物
JP5767580B2 (ja) 薬剤送達のためのリポソームおよびその調製方法
JP5778160B2 (ja) ｓＰＬＡ２加水分解性リポソームを含む医薬組成物
US20040101553A1 (en) Platinum aggregates and process for producing the same
EP3532067B1 (en) Liposomal formulation for use in the treatment of cancer
EP3302435B1 (en) Liposome loading
EP1448165B1 (en) Lipid carrier compositions and methods for improved drug retention
CN109983013A (zh) 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
US20110020428A1 (en) Gel-stabilized liposome compositions, methods for their preparation and uses thereof
US20050129753A1 (en) Method for drug loading in liposomes
EP4209229A1 (en) Liposome preparation containing antibacterial drug
JP2024505154A (ja) ウチデロンリポソーム組成物、及びその製造方法並びに使用
EP1731172B1 (en) Liposome preparation
CN115666552B (zh) 含有乙二胺四乙酸或其盐的艾日布林或其可药用盐脂质体
JP7862882B2 (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
WO2010095964A1 (en) A method for amphiphilic drug loading in liposomes by ion gradient
EP4552632A1 (en) Liposomal composition containing mild acidic active agent
WO2010092590A2 (en) Process for the preparation of doxorubicin liposomes
CA3024951C (en) Liposome loading
OA20783A (en) Carotenoid compositions and uses thereof
HK40009841A (en) Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 DEC 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 DEC 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired